On September 8, 2023 our lives changed forever when our wonderful 3-year-old Juliette was diagnosed with a rare, aggressive form of brain cancer called PFA ependymoma.

Ependymoma is the third most common pediatric central nervous system (CNS) tumor, accounting for 8-10% of all diagnoses. Unfortunately, outcomes for ependymomas are poor, with five-year overall survival of 50-64%.

The treatments for ependymoma have not changed in any significant way for decades, which is why we need a new approach.

Ependymoma Research Foundation is committed to identifying and supporting novel research projects that will lead to an effective treatment for ependymoma.